Clinical Trial

A Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children.

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The goal of this multi-center, randomized, double-blind, placebo-controlled study is to evaluate the safety and immunogenicity of CHIKV VLP Vaccine in children 1 to \<12 years of age.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-05-27; most recent amendment 2026-03-20.
Status change: Not Yet Recruiting → Recruiting 2025-07-15
Trial Details
NCT Number NCT07003984
Lead Sponsor Bavarian Nordic
Conditions Chikungunya Virus
Enrollment 720 participants
Start Date 2025-06-05
Primary Completion 2028-12 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-03-24